We are live on ! Find out more
KTTA icon

Pasithea Therapeutics

12 hedge funds and large institutions have $122K invested in Pasithea Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 12 → 12 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

0.47% less ownership

Funds ownership: 1.45% → 0.98% (-0.47%)

53% less capital inflows, than outflows

Capital inflows: $49.4K | Capital outflows: $105K

Holders
12
Holders Change
–
Holders Change %
0%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

KTTA Hedge Fund Activity: Q3 2023 in Review

12 of the 6,317 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q3 2023, worth a combined $122K — down 34% from $184K a quarter earlier.

Fund positioning in KTTA was balanced in Q3 2023: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 3 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $21.1K. The largest seller was Vanguard Group, exiting entirely with an estimated $59.3K sold.

  • 12 institutional investors held Pasithea Therapeutics (KTTA) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $122K of Pasithea Therapeutics stock for Q3 2023, down 34% quarter-over-quarter.
  • 4 funds opened new Pasithea Therapeutics positions in Q3 2023 and 4 closed out, a net change of 0 holders.
  • The largest Pasithea Therapeutics buyer in Q3 2023 was Susquehanna International Group, an estimated $21.1K added.
  • The largest Pasithea Therapeutics seller in Q3 2023 was Vanguard Group, an estimated $59.3K sold.

Based on aggregated 13F filings for Q3 2023.